NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER FOR CANCER

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Lung cancer is the leading cause of cancer death in the US. The overall goal of the NYU Clinical and Epidemiologic Center for the Early Detection of Cancer is to develop and prospectively follow large, geographically dispersed populations of former and active union members of varying environmental cancer risk, to identify preneoplastic cellular changes and lesions, and to detect early cancers. The NYU population will consist of many individuals with a history of smoking and/or workplace exposures. They will be drawn from the building trade unions, where past exposure to asbestos was common among utility workers, asbestos insulators, boilermakers, sheet-metal workers, carpenters, and pipefitters. The NYU Center will have a subcontract to screen active and former workers associated with a nuclear weapons facility in Texas. The NYU Clinical and Epidemiologic Center will facilitate recruitment and sampling of a large cohort of high-risk, blue- collarn workers and that assays for DNA-adducts on p53 and K-ras genes, deregulation of the cyclin-cyclin dependent kinases, deregulation of signaling and Rb pathways, and other bioassays for oncogenes and tumor suppressor genes will detect preneoplastic conditions or cancer in the earliest and most treatable stages. Fluorescence bronchoscopy will be performed on certain high risk individuals for bronchial brush and mucosal biopsies to evaluate cell-cycle deregulation.